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This editorial refers to ‘Midlife blood pressure change and
left ventricular mass and remodelling in older age in the
1946 British Birth Cohort Study’†, by A.K. Ghosh et al. on
page 3287.
The 1946 Medical Research Council National Survey of Health and
Development (MRC-NSHD) is the longest running birth cohort in
the UK. Making use of this unique resource, Ghosh and colleagues
have now demonstrated that left ventricular mass index (LVMI) and
relativewall thickness at age 60–64 were associated with blood pres-
sure (BP) or use of antihypertensive drugs from 36 years of age
onwards, independent of current BP or treatment status.1 Moreover,
the rate of BP increase over time rather than the absolute BP level at a
given age determined the LVMI at 60–64 years.1 Ghosh and collea-
gues have to be congratulated for their meticulous analysis of longi-
tudinal data spanning 28 years. Nevertheless, several issues cannot
be disregarded in the interpretation of the results. First, as in all lon-
gitudinal studies, the attrition rate was high. Of 5362 initially enrolled
participants, only 2856 were invited for echocardiography from 2006
until 2011. Invitationswere not sent to thosewhohad died (n ¼ 778),
were living abroad (n ¼ 570), had previously withdrawn from the
study (n ¼ 594), or had been lost to follow-up (n ¼ 564). Of those
invited, 539 (18.9%) accepted to be visited at home, but only 1653
(57.8%) underwent echocardiography and 1480 (51.8%) had analys-
able images. The authors argued that participants who opted for a
home visit had higher BP and were less healthy, and that exclusion
of this unhealthy group might have weakened the observed associa-
tions between left ventricular structure and BP. While this specula-
tion might be true, it disregarded that half of the cohort was lost
between 1946 and the time of invitation for echocardiography.
A second major issue was that at age 36 and 43, the Hawksley
Random Zero sphygmomanometer was used, while an Omron
HEM-705 was used at ages 53 and 60–64. The auscultatory approach
involves measuring systolic and diastolic BP, whereas automated
oscillometric devices, such as the Omron HEM-705, extrapolate sys-
tolic and diastolic BP from the measured mean arterial pressure. The
Hawksley Random Zero sphygmomanometer was designed to
reduce observer bias.2 However, as first reported by O’Brien2 and
confirmed by others,3 it underestimates BP, on average by as much
as 3.8 mmHg systolic and 7.5 mmHg diastolic.4 This underestimation
increases with higher BP levels.5 Based on a German study,5 Ghosh
and colleagues applied linear regression analysis including sex, age,
and BP level as covariables to adjust the random zero measurements
and to achieve compatibility with the later oscillometric readings.
Although Ghosh and colleagues might have had no alternative, one
wonders to what extent a study done in Germany with different
devices5 is applicable to MRC-NSHD and whether auscultatory
and oscillometric estimates of BP can be used interchangeably. The
authors might have considered more robust ways for adjusting for
the use of two different devices, for instance by setting up their
own reproducibility study or by comparing BP slopes obtained
before and after age 53.
Another potentially clinically important observation emerging
from the study of Ghosh et al.1 is that people with treated hyperten-
sion had higher LVMI, even afteradjustment for currentBP. However,
the MRC-NSHD report provided no information on the persistence
of treatmentover time, the BP levels reachedon treatment, orexcep-
tion made for the treatment status at 60–64 years on the drug classes
prescribed. Nevertheless, Ghosh’s observations1 are in line with the
results of the Pressioni Arteriose Monitorate E Loro Associazioni
(PAMELA) study.6 The 2051 participants were categorized based
on their office, home, or 24 h BP into normotensive individuals and
patients with hypertension, who were untreated, treated but not
controlled, or treated and controlled.6 Compared with the normo-
tensive group, LVMI was higher not only in untreated hypertensive
patients, but also in treated uncontrolled patients and even in
treated and controlled patients (79.7 vs. 91.3, 103.4 and 94.3 g/m2,
respectively). The samewas true for the prevalence of left ventricular
hypertrophy (4.2 vs. 14.3, 28.7, and 19.0%, respectively).6 Ghosh and
colleagues1 speculated that an elevated BP in midlife causes a ‘legacy’
of cardiac damage including interstitial and perivascular fibrosis that
may be difficult to reverse even if BP is subsequently well controlled
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with medication. In line with this hypothesis, we previously demon-
strated that normalization of the ambulatory BP on antihypertensive
drug treatment does not eliminate the lifetime cardiovascular burden
associated with the previous elevated BP,7 perhaps because blood
pressure normalization by itself does not address other risk factors
that cluster with hypertension.
Vasan and colleagues evaluated association of current BP (at base-
line), recent antecedentBP (averageof readings forall available exam-
inations 1–10 years before baseline), and remote antecedent BP
(average for all available examinations 11–20 years before baseline)
with the 10-year cardiovascular risk in 2313 Framingham partici-
pants.4 They reported that antecedent BP is a major determinant
of the future cardiovascular risk above and beyond current BP.4 In
a subsequent report,8 the Framingham investigators noticed that
higher midlife BP and body mass index predict heart failure later in
life. A pooled analysis of seven US cohorts involved 61 585 subjects,
700 000 person-years of follow-up starting at age 55, and prior BP
data over an average of 14 years.9 Individuals who maintained or
decreased their BP to normal levels had the lowest remaining lifetime
risk for cardiovascular disease, 22–41%, compared with individuals
who had or developed hypertension by 55 years of age, 42–69%.9
Among 4217 Framingham study participants, who underwent up to
four serial echocardiographic examinations, sex, age, body mass
index, systolic BP, antihypertensive treatment, smoking, and diabetes
mellitus were the determinants of tracking of left ventricular mass
over the adult life course.10 At variance with Ghosh’s findings,1
women experienced a steeper increase in left ventricular mass
with advancing age and increasing body mass index compared with
men.10 We also found in a large international database that the risk
associated with the level of the ambulatory BP increased more
steeply in women than in men (Figure 1).11
In conclusion, the report by Ghosh and colleagues1 confirms the
results of previously published cohort studies4,8 –10 that all showed
that BP early in life is a major determinant of adverse cardiovascular
outcomes later in life. Investigators in the Global Burden of Diseases
Study2010 reported thathigh bloodpressure is the leading risk factor
for the global disease burden, and is estimated to cause 9.4 million
deaths every year—more than half of the estimated 17 million
deaths per year caused by cardiovascular disease.12 As demonstrated
by Ghosh et al.1 and other investigators,4,7– 10 antihypertensive drug
treatment does not completely reverse the risk associated with the
BP burden early in life, in particular when the BP load is allowed to
persist for many years or in the presence of other risk factors. The
take home message of Ghosh’s report is therefore an appeal to over-
come therapeutic inertia. Patients and caregivers should commence
and maintain antihypertensive drug treatment as soon as the diagno-
sis of hypertension is confirmed, preferably by ambulatory BP mon-
itoring,13 and should not rest until BP levels are at goal. In contrast to
Ghosh’s contention, women are a particularly vulnerable group10,11
and represent a group in whom early treatment of hypertension
represents an opportunity to increase years and quality of life.
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